Literature DB >> 24360267

Prevalence of antibiotic resistance in US hospitals.

John Edelsberg1, Derek Weycker2, Rich Barron3, Xiaoyan Li3, Hongsheng Wu4, Gerry Oster1, Sejal Badre3, Wendy J Langeberg3, David J Weber5.   

Abstract

The percentage of isolates resistant to essential antibiotics among clinically significant bacterial pathogens was evaluated using data from 80089 qualifying admissions in 19 US hospitals (2007-2010). Percentage resistant was highest for the following pathogen/antibiotic pairs: Enterococcus faecium/vancomycin (87.1% [95% CI 86.0-88.1] of 4024 isolates), Staphylococcus aureus/oxacillin-methicillin (56.8% [56.1-57.4] of 23477 isolates), S. aureus/clindamycin (39.7% [39.1-40.4] of 21133 isolates), Pseudomonas aeruginosa/fluoroquinolones (32.6% [31.8-33.5] of 10982 isolates), and Escherichia coli/fluoroquinolones (31.3% [30.8-31.8] of 30715 isolates). The percentage resistant was 3.9% (3.2-4.9) for E. faecium/daptomycin (n = 2029 isolates). While these results are consistent with those from earlier studies in many respects, the percentage of E. faecium isolates resistant to daptomycin, while still small, is higher than has been reported to date.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; Bacterial; Drug resistance

Mesh:

Substances:

Year:  2013        PMID: 24360267     DOI: 10.1016/j.diagmicrobio.2013.11.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  28 in total

1.  Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.

Authors:  Kwaku Kyei-Baffour; Haroon Mohammad; Mohamed N Seleem; Mingji Dai
Journal:  Bioorg Med Chem       Date:  2019-03-19       Impact factor: 3.641

2.  β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  Enterococci and Their Interactions with the Intestinal Microbiome.

Authors:  Krista Dubin; Eric G Pamer
Journal:  Microbiol Spectr       Date:  2014-11

Review 4.  Immunomodulation therapy offers new molecular strategies to treat UTI.

Authors:  Daniel Butler; Ines Ambite; Murphy Lam Yim Wan; Thi Hien Tran; Björn Wullt; Catharina Svanborg
Journal:  Nat Rev Urol       Date:  2022-06-22       Impact factor: 16.430

Review 5.  Antibacterial Activity of Medicinal Plants against Uropathogenic Escherichia coli.

Authors:  Razan Salman Marouf; Joseph Arsene M Mbarga; Andrey V Ermolaev; Irina V Podoprigora; Irina P Smirnova; Natalia V Yashina; Anna V Zhigunova; Aliya V Martynenkova
Journal:  J Pharm Bioallied Sci       Date:  2022-05-19

6.  An aryl isonitrile compound with an improved physicochemical profile that is effective in two mouse models of multidrug-resistant Staphylococcus aureus infection.

Authors:  Haroon Mohammad; Kwaku Kyei-Baffour; Nader S Abutaleb; Mingji Dai; Mohamed N Seleem
Journal:  J Glob Antimicrob Resist       Date:  2019-04-30       Impact factor: 4.035

7.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

8.  Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.

Authors:  Angelica Zhang; Jeffrey L Veesenmeyer; Alan R Hauser
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

9.  Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.

Authors:  Guiqing Wang; Sitharthan Kamalakaran; Abhay Dhand; Weihua Huang; Caroline Ojaimi; Jian Zhuge; Leslie Lee Yee; Pramod Mayigowda; Pavan Kumar Makam Surendraiah; Nevenka Dimitrova; John T Fallon
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

Review 10.  Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.

Authors:  Subhashis Mitra; Usman Saeed; Daniel H Havlichek; Gary E Stein
Journal:  Infect Drug Resist       Date:  2015-07-06       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.